Overview

A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension

Status:
Completed

Trial end date:
2017-07-03

Target enrollment:

Participant gender:

Summary

The purpose of the study is to examine how preservative free tafluprost ophthalmic solution (0.0015%) is distributed in blood circulation after ocular administration in children who have glaucoma or elevated intraocular pressure. Tolerance to the drug and safety in general will also be assessed.

Phase:

Phase 1

Details

Lead Sponsor:

Santen Oy

Treatments:

Ophthalmic Solutions
Pharmaceutical Solutions